"It's a paradigm shift." This is how Prof. Ulf Teichgräber, Director of the Institute of Diagnostic and Interventional Radiology at the University Hospital Jena, describes the improvement in communication with sponsors and CROs through the use of mint Lesion™. Together, Ms. Laura Graziani, study coordinator, Ms. Elisabeth Lammers, study assistant/MTRA, and Prof. Teichgräber describe their journey towards a successful clinical trial center that can now manage up to 40 clinical trials simultaneously.
Where results previously had to be painstakingly entered into Excel spreadsheets, mint Lesion™ has taken over the evaluation of all findings since its introduction in 2015, thus increasing the objectivity and validity of the study results.
Workflow optimization, increased efficiency and reduced errors in clinical trials
Related Resources
Related Resources
University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy
A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…
Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™
Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…
New Technique Speeds Up Whole-Body MRI for Children Without Sacrificing Image Quality, Study Finds
As we mark Childhood Cancer Awareness Month, we would like to highlight the progress achieved in the realm of cancer diagnostics. A recent study led…